Form 4: Standard BioTools Insider Boosts Stake by 525,000 Shares

Casdin Partners Master Fund, L.P., a 10% owner and director, increased its beneficial ownership in Standard BioTools Inc. by acquiring 525,000 shares of common stock.

Summary

• Casdin Partners Master Fund, L.P., a 10% owner and director of Standard BioTools Inc. (LAB), acquired an additional 525,000 shares of common stock.
• The acquisitions occurred over three separate transactions: 200,000 shares on August 22, 2025, at $1.2634 per share; 200,000 shares on August 25, 2025, at a weighted average price of $1.2409 per share; and 125,000 shares on August 26, 2025, at $1.2635 per share.
• Following these transactions, Casdin Partners Master Fund, L.P.'s indirect beneficial ownership increased to 60,275,000 shares.
• Other related entities and individuals, including Eli Casdin (managing member of Casdin Capital and Casdin Partners GP), also hold significant beneficial ownership in Standard BioTools Inc.
• Eli Casdin directly owns 2,901,062 shares.
• Casdin Private Growth Equity Fund II, L.P. indirectly owns 13,939,637 shares.
• Casdin Private Growth Equity Fund, L.P. indirectly owns 2,744,219 shares.

Sentiment

Score: 8

Explanation: The significant insider buying by a major institutional investor and director signals strong confidence in the company's current valuation and future performance, which is a highly positive indicator for the market.

Positives

• Significant insider buying by a 10% owner and director, Casdin Partners Master Fund, L.P., indicates confidence in the company's future prospects.
• The acquisition of 525,000 shares demonstrates a substantial commitment from a major institutional investor.
• The purchases were made at prices ranging from $1.2311 to $1.2635, suggesting a belief in value at current levels.

Future Outlook

NA

Management Comments

• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the 'Exchange Act'), each of the Reporting Persons may be deemed directors by deputization of the Issuer.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

NA

Related Party Transactions

• Acquisition of 525,000 shares of common stock by Casdin Partners Master Fund, L.P., an entity related to Eli Casdin, a director and 10% owner of Standard BioTools Inc.

Stakeholder Impact

• Shareholders: The insider buying could be perceived as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: Reinforces alignment between a significant investor/director and the company's performance.

Key Dates

Recommendation

The substantial insider buying by Casdin Partners Master Fund, L.P., a 10% owner and director, at current price levels, suggests a strong belief in the intrinsic value and future growth potential of Standard BioTools Inc. Such a significant investment by a well-informed party typically signals undervaluation or anticipated positive developments, making it a compelling 'buy' signal for seasoned investors.

Keywords

Standard BioTools, LAB, Casdin Partners, Insider Buying, SEC Form 4, Beneficial Ownership, Equity Acquisition, Biotech Investment, Director Purchase, 10% Owner